(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 62.89% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Ascendis Pharma A's revenue in 2025 is $418,978,409.On average, 7 Wall Street analysts forecast ASND's revenue for 2025 to be $44,838,910,233, with the lowest ASND revenue forecast at $38,639,175,688, and the highest ASND revenue forecast at $54,984,675,222. On average, 7 Wall Street analysts forecast ASND's revenue for 2026 to be $75,454,753,671, with the lowest ASND revenue forecast at $64,458,304,143, and the highest ASND revenue forecast at $94,167,021,819.
In 2027, ASND is forecast to generate $110,964,172,515 in revenue, with the lowest revenue forecast at $87,234,461,719 and the highest revenue forecast at $129,366,317,384.